Whole Cell Immunization Introduction for Hybridoma Generation

Whole cell immunization is an important immunization strategy that is often used when the antigen of interest is unknown, and we need to prepare the corresponding antibody. In this approach, we use the whole cell as an antigen for animal immunization, which is particularly suitable for preparing of tumor antibodies.

Treatment of Whole Cell Immunization

When whole cell immunization is used for antibody production from hybridoma, the cells need to be appropriately processed depending on the specific situation. When whole cells are used as an immunogen, it is necessary to wash out the serum in the medium. We recommend using intact cells directly as an immunogen without breaking them up since the intact cells are more granular and exogenous, which can enhance the immune effect. When tissue-derived cells and cultured cells are used as an immunogen, intraperitoneal immunization is preferred, but subcutaneous immunization is not recommended.

Advantages of Whole Cell Immunization

Using whole tumor cells as immunogens has several advantages over using specific protein or peptide oncogenes. Tumor cells provide a source of all potential antigens without the need to identify a specific type of cancer. Using whole cells as antigens allows the simultaneous targeting of multiple tumor antigens, thereby bypassing the problem of tumor antigen loss. Additionally, by comparing immune responses before and after immunization and correlating responses with prognosis, immune lymphocyte and serologic responses can be used to identify novel tumor antigens or to classify the importance of responses to specific tumor antigens.

Limitations of Whole Cell Immunization

The whole cell used in whole cell immunization has been genetically engineered to express cytokines, chemokines, or costimulatory molecules to stimulate an immune response to injected irradiated tumor cells. From previous studies, the immune response induced by whole cell immunization was evaluated by measuring the delayed-type hypersensitivity response to autologous tumor cells. Although tumor cells themselves do not trigger hypersensitivity reactions, hypersensitivity reactions have been observed to be associated with a survival benefit in the body given the genetically modified vaccine cells. In response to this phenomenon, methods to alleviate hypersensitivity caused by whole-cell immunity need to be further developed.

The most significant limitation of whole cell immunization is the multiple inhibitory signals on T cells and antigen-presenting cells, which are responsible for activating T-cell responses prevent effective immune activation and recognition of a patient's growing tumor. This contributes to the lack of clinical activity of current whole cell immunization-based vaccines. However, with research progress, drugs that regulate these inhibitory signals have shown clinical responses, which can broaden the application of whole cell immunization in therapy and diagnosis.

Creative Biolabs shares our experience regarding the field of whole cell immunization, and we hope that your research processes well.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: